610 related articles for article (PubMed ID: 32923158)
21. Elucidating T Cell and B Cell Responses to SARS-CoV-2 in Humans: Gaining Insights into Protective Immunity and Immunopathology.
Khanolkar A
Cells; 2021 Dec; 11(1):. PubMed ID: 35011627
[TBL] [Abstract][Full Text] [Related]
22. Recent advances in vaccine and immunotherapy for COVID-19.
Rabaan AA; Al-Ahmed SH; Sah R; Al-Tawfiq JA; Al-Qaaneh AM; Al-Jamea LH; Woodman A; Al-Qahtani M; Haque S; Harapan H; Bonilla-Aldana DK; Kumar P; Dhama K; Rodriguez-Morales AJ
Hum Vaccin Immunother; 2020 Dec; 16(12):3011-3022. PubMed ID: 33156739
[TBL] [Abstract][Full Text] [Related]
23. SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection.
Altmann DM; Boyton RJ
Sci Immunol; 2020 Jul; 5(49):. PubMed ID: 32680954
[TBL] [Abstract][Full Text] [Related]
24. Understanding the dynamics of COVID-19; implications for therapeutic intervention, vaccine development and movement control.
Salvamani S; Tan HZ; Thang WJ; Ter HC; Wan MS; Gunasekaran B; Rhodes A
Br J Biomed Sci; 2020 Oct; 77(4):168-184. PubMed ID: 32942955
[TBL] [Abstract][Full Text] [Related]
25. Overlap of immunotherapy-related pneumonitis and COVID-19 pneumonia: diagnostic and vaccine considerations.
Abid MB
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931473
[TBL] [Abstract][Full Text] [Related]
26. Ferritin nanoparticle-based SARS-CoV-2 RBD vaccine induces a persistent antibody response and long-term memory in mice.
Wang W; Huang B; Zhu Y; Tan W; Zhu M
Cell Mol Immunol; 2021 Mar; 18(3):749-751. PubMed ID: 33580169
[No Abstract] [Full Text] [Related]
27. Characterization of pre-existing and induced SARS-CoV-2-specific CD8
Schulien I; Kemming J; Oberhardt V; Wild K; Seidel LM; Killmer S; Sagar ; Daul F; Salvat Lago M; Decker A; Luxenburger H; Binder B; Bettinger D; Sogukpinar O; Rieg S; Panning M; Huzly D; Schwemmle M; Kochs G; Waller CF; Nieters A; Duerschmied D; Emmerich F; Mei HE; Schulz AR; Llewellyn-Lacey S; Price DA; Boettler T; Bengsch B; Thimme R; Hofmann M; Neumann-Haefelin C
Nat Med; 2021 Jan; 27(1):78-85. PubMed ID: 33184509
[TBL] [Abstract][Full Text] [Related]
28. Immunology Lessons from the SARS-CoV-2 Pandemic.
Yokoyama WM; Hogquist KA; O'Shea JJ
Annu Rev Immunol; 2021 Apr; 39():v-vii. PubMed ID: 33939926
[No Abstract] [Full Text] [Related]
29. Durable tracking anti-SARS-CoV-2 antibodies in cancer patients recovered from COVID-19.
Huang Y; Yu J; Li D; He K; Liu W; Wang L; Chen Y; Xie C; Wu X
Sci Rep; 2021 Aug; 11(1):17381. PubMed ID: 34462453
[TBL] [Abstract][Full Text] [Related]
30. Multiepitope Subunit Vaccine Design against COVID-19 Based on the Spike Protein of SARS-CoV-2: An
Dar HA; Waheed Y; Najmi MH; Ismail S; Hetta HF; Ali A; Muhammad K
J Immunol Res; 2020; 2020():8893483. PubMed ID: 33274246
[TBL] [Abstract][Full Text] [Related]
31. IL-7 in SARS-CoV-2 Infection and as a Potential Vaccine Adjuvant.
Bekele Y; Sui Y; Berzofsky JA
Front Immunol; 2021; 12():737406. PubMed ID: 34603318
[TBL] [Abstract][Full Text] [Related]
32. Endemic SARS-CoV-2 will maintain post-pandemic immunity.
Veldhoen M; Simas JP
Nat Rev Immunol; 2021 Mar; 21(3):131-132. PubMed ID: 33402727
[TBL] [Abstract][Full Text] [Related]
33. A novel STING agonist for cancer immunotherapy and a SARS-CoV-2 vaccine adjuvant.
Wu JJ; Zhao L; Han BB; Hu HG; Zhang BD; Li WH; Chen YX; Li YM
Chem Commun (Camb); 2021 Jan; 57(4):504-507. PubMed ID: 33331360
[TBL] [Abstract][Full Text] [Related]
34. Fighting the SARS-CoV-2 pandemic requires a global approach to understanding the heterogeneity of vaccine responses.
Tomalka JA; Suthar MS; Deeks SG; Sekaly RP
Nat Immunol; 2022 Mar; 23(3):360-370. PubMed ID: 35210622
[TBL] [Abstract][Full Text] [Related]
35. Repeated Exposure to Subinfectious Doses of SARS-CoV-2 May Promote T Cell Immunity and Protection against Severe COVID-19.
De Angelis ML; Francescangeli F; Rossi R; Giuliani A; De Maria R; Zeuner A
Viruses; 2021 May; 13(6):. PubMed ID: 34067349
[TBL] [Abstract][Full Text] [Related]
36. Functional responsiveness of memory T cells from COVID-19 patients.
Tavukcuoglu E; Horzum U; Cagkan Inkaya A; Unal S; Esendagli G
Cell Immunol; 2021 Jul; 365():104363. PubMed ID: 33905951
[TBL] [Abstract][Full Text] [Related]
37. Immune responses to COVID-19 vaccines in patients with cancer: Promising results and a note of caution.
Griffiths EA; Segal BH
Cancer Cell; 2021 Aug; 39(8):1045-1047. PubMed ID: 34242573
[TBL] [Abstract][Full Text] [Related]
38. A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge.
Yahalom-Ronen Y; Tamir H; Melamed S; Politi B; Shifman O; Achdout H; Vitner EB; Israeli O; Milrot E; Stein D; Cohen-Gihon I; Lazar S; Gutman H; Glinert I; Cherry L; Vagima Y; Lazar S; Weiss S; Ben-Shmuel A; Avraham R; Puni R; Lupu E; Bar-David E; Sittner A; Erez N; Zichel R; Mamroud E; Mazor O; Levy H; Laskar O; Yitzhaki S; Shapira SC; Zvi A; Beth-Din A; Paran N; Israely T
Nat Commun; 2020 Dec; 11(1):6402. PubMed ID: 33328475
[TBL] [Abstract][Full Text] [Related]
39. Scent of a vaccine.
Lund FE; Randall TD
Science; 2021 Jul; 373(6553):397-399. PubMed ID: 34437109
[No Abstract] [Full Text] [Related]
40. Covid-19 vaccines: delivering protective immunity.
Sewell HF; Agius RM; Kendrick D; Stewart M
BMJ; 2020 Dec; 371():m4838. PubMed ID: 33334862
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
